文献速递类风湿关节炎

类风湿关节炎患者起始托法替布前接种带状疱疹活疫苗的安全性与免疫原性:随机II期试验

The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.
PubMed 文献 · Arthritis Rheumatol · 2017-09-06

本项II期、14周、安慰剂对照试验纳入50岁及以上、接受甲氨蝶呤背景治疗的活动性类风湿关节炎(RA)患者,接种带状疱疹活疫苗(LZV)后2–3周随机加用托法替布5 mg每日两次或安慰剂。接种后6周,两组VZV特异性IgG与T细胞的几何平均倍数升高相近;除1例接种前缺乏VZV免疫者出现疫苗播散外,接种总体安全。

要点

  • LZV接种后2–3周起始托法替布,未明显削弱VZV特异性体液与细胞免疫应答。
  • 接种前缺乏VZV免疫力者接种后出现皮肤疫苗播散,停药抗病毒后缓解。
  • 托法替布组严重不良事件3例(5.5%),安慰剂组0例(0.0%)。

核心结论

  • RA患者接种LZV后2–3周起始托法替布,其VZV特异性体液和细胞免疫应答与安慰剂组相似,接种总体安全,但接种前无VZV免疫力者存在疫苗播散风险。

主要发现

  • 接种后6周VZV特异性IgG几何平均倍数升高托法替布组2.11、安慰剂组1.74。
  • 接种后6周VZV特异性T细胞几何平均倍数升高托法替布组1.50、安慰剂组1.29。
  • 严重不良事件托法替布组3例(5.5%)、安慰剂组0例(0.0%)。
  • 1例接种前缺乏VZV免疫力的患者,在起始托法替布后2天(接种后16天)出现皮肤疫苗播散,停用托法替布并抗病毒治疗后缓解。

关键数值与推荐

  • 主要终点为接种后6周VZV特异性IgG几何平均倍数升高。
  • 次要终点包括接种后6周VZV特异性T细胞(斑点形成细胞数/10^6外周血单个核细胞)几何平均倍数升高。
  • 免疫应答于基线及接种后2周、6周、14周评估;托法替布5 mg每日两次或安慰剂于接种后2–3周开始。

临床怎么用

  • 对50岁及以上拟起始托法替布的RA患者,可考虑在启动托法替布前接种LZV,并于接种后2–3周再开始托法替布。
  • 接种前应评估患者既往VZV免疫力,缺乏者接种后需警惕疫苗播散。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with rheumatoid arthritis (RA) are at increased risk of herpes zoster, and vaccination is recommended for patients ages 50 years and older, prior to starting treatment with biologic agents or tofacitinib. Tofacitinib is an oral JAK inhibitor for the treatment of RA. We evaluated its effect on the immune response and safety of live zoster vaccine (LZV). METHODS: In this phase II, 14-week, placebo-controlled trial, patients ages 50 years and older who had active RA and were receiving background methotrexate were given LZV and randomized to receive tofacitinib 5 mg twice daily or placebo 2-3 weeks postvaccination. We measured humoral responses (varicella zoster virus [VZV]-specific IgG level as determined by glycoprotein enzyme-linked immunosorbent assay) and cell-mediated responses (VZV-specific T cell enumeration, as determined by enzyme-linked immunospot assay) at baseline and 2 weeks, 6 weeks, and 14 weeks postvaccination. End points included the geometric mean fold rise (GMFR) in VZV-specific IgG levels (primary end point) and T cells (number of spot-forming cells/106 peripheral blood mononuclear cells) at 6 weeks postvaccination. RESULTS: One hundred twelve patients were randomized to receive tofacitinib (n = 55) or placebo (n = 57). Six weeks postvaccination, the GMFR in VZV-specific IgG levels was 2.11 in the tofacitinib group and 1.74 in the placebo group, and the VZV-specific T cell GMFR was similar in the tofacitinib group and the placebo group (1.50 and 1.29, respectively). Serious adverse events occurred in 3 patients in the tofacitinib group (5.5%) and 0 patients (0.0%) in the placebo group. One patient, who lacked preexisting VZV immunity, developed cutaneous vaccine dissemination 2 days after starting tofacitinib (16 days postvaccination). This resolved after tofacitinib was discontinued and the patient received antiviral treatment. CONCLUSION: Patients who began treatment with tofacitinib 2-3 weeks after receiving LZV had VZV-specific humoral and cell-mediated immune responses to LZV similar to those in placebo-treated patients. Vaccination appeared to be safe in all of the patients except 1 patient who lacked preexisting VZV immunity.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Winthrop KL, Wouters AG, Choy EH, et al. The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial. Arthritis Rheumatol. 2017. PMID: 28845577. doi:10.1002/art.40187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。